Asieris completed enrollment for its China Phase II Trial of APL-1202

In October 2015, Asieris’ Clinical Research Department announced the successful completion of subject enrollment for our key clinical research project “A Phase II Clinical Trial of APL-1202, an Oral metaP2 Inhibitor, in Patients with High-Risk NMIBC and relapsed after Intravesical Therapies”.  

The China Phase II Clinical Trial of APL-1202 is intended to treat patients with high-risk NMIBC who had failed inravesical chemo or BCG therapy, and currently is the only orally administered drug in the world under clinical investigation for treating NMIBC. Due to the very high standards of enrollment requirements, as well as a broad geographic base covering Zhejiang, Jiangsu, Tianjin, Hubei, Jiangxi and other provinces and cities in addition to Beijing, Shanghai, Guangzhou, the subject recruitment has faced a number of challenges. Through the relentless and dedicated efforts and cooperation of all the clinical centers and CRO, the Clinical Research Department has successfully completed the enrollment in 18 months.